Biopharma firm Biohaven's Q3 net loss widens to $173.4 mln

Reuters

Nov 10

Biopharma firm Biohaven's Q3 net loss widens to $173.4 mln

Overview

Biohaven reports Q3 net loss of $173.4 mln, operating expenses at $169.4 mln
Company initiates strategic cost optimization to reduce annual direct R&D spend by 60%
Biohaven focuses resources on late-stage programs for epilepsy, depression, and immune diseases

Outlook

Biohaven expects top-line results from Opakalim Phase 2 study in depression in 4Q 2025
Company plans to initiate Phase 2 trial for Taldefgrobep alfa in obesity in 4Q 2025
Biohaven aims to reduce annual direct R&D spend by approximately 60%

Result Drivers

COST OPTIMIZATION - Biohaven initiated strategic cost optimization to focus on late-stage clinical programs

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 Net Income		-$173.44 mln
Q3 Basic EPS		-$1.64
Q3 Operating Expenses		$169.38 mln
Q3 Profit From Operations		-$169.38 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 15 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Biohaven Ltd is $27.00, about 69.4% above its November 7 closing price of $8.26

Press Release: ID:nPn8ktwCsa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2582732098"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2582732098\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2582732098?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-10 20:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582732098","market":"nz","top_or_hot":-1,"title":"Biopharma firm Biohaven's Q3 net loss widens to $173.4 mln","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Biopharma firm Biohaven's Q3 net loss widens to $173.4 mln</title></head><body><p><span>Overview</span></p><ul><li><p>Biohaven reports Q3 net loss of $173.4 mln, operating expenses at $169.4 mln</p></li><li><p>Company initiates strategic cost optimization to reduce annual direct R&amp;D spend by 60%</p></li><li><p>Biohaven focuses resources on late-stage programs for epilepsy, depression, and immune diseases</p></li></ul><p><span>Outlook</span></p><ul><li><p>Biohaven expects top-line results from Opakalim Phase 2 study in depression in 4Q 2025</p></li><li><p>Company plans to initiate Phase 2 trial for Taldefgrobep alfa in obesity in 4Q 2025</p></li><li><p>Biohaven aims to reduce annual direct R&amp;D spend by approximately 60%</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>COST OPTIMIZATION - Biohaven initiated strategic cost optimization to focus on late-stage clinical programs</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$173.44 mln</p></td><td></td></tr><tr><td><p>Q3 Basic EPS</p></td><td></td><td><p>-$1.64</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$169.38 mln</p></td><td></td></tr><tr><td><p>Q3 Profit From Operations</p></td><td></td><td><p>-$169.38 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 15 \"strong buy\" or \"buy\", 3 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Biohaven Ltd is $27.00, about 69.4% above its November 7 closing price of $8.26</p></li></ul><p>Press Release: <span>ID:nPn8ktwCsa</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biopharma firm Biohaven's Q3 net loss widens to $173.4 mln</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiopharma firm Biohaven's Q3 net loss widens to $173.4 mln\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-10 20:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Biopharma firm Biohaven's Q3 net loss widens to $173.4 mln</title></head><body><p><span>Overview</span></p><ul><li><p>Biohaven reports Q3 net loss of $173.4 mln, operating expenses at $169.4 mln</p></li><li><p>Company initiates strategic cost optimization to reduce annual direct R&amp;D spend by 60%</p></li><li><p>Biohaven focuses resources on late-stage programs for epilepsy, depression, and immune diseases</p></li></ul><p><span>Outlook</span></p><ul><li><p>Biohaven expects top-line results from Opakalim Phase 2 study in depression in 4Q 2025</p></li><li><p>Company plans to initiate Phase 2 trial for Taldefgrobep alfa in obesity in 4Q 2025</p></li><li><p>Biohaven aims to reduce annual direct R&amp;D spend by approximately 60%</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>COST OPTIMIZATION - Biohaven initiated strategic cost optimization to focus on late-stage clinical programs</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$173.44 mln</p></td><td></td></tr><tr><td><p>Q3 Basic EPS</p></td><td></td><td><p>-$1.64</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$169.38 mln</p></td><td></td></tr><tr><td><p>Q3 Profit From Operations</p></td><td></td><td><p>-$169.38 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 15 \"strong buy\" or \"buy\", 3 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Biohaven Ltd is $27.00, about 69.4% above its November 7 closing price of $8.26</p></li></ul><p>Press Release: <span>ID:nPn8ktwCsa</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nL1N3WM0D3:1","article_id":"2582732098","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582732098","pubTimestamp":1762776397,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Biopharma firm Biohaven's Q3 net loss widens to $173.4 mlnOverviewBiohaven reports Q3 net loss of $173.4 mln, operating expenses at $169.4 mlnCompany initiates strategic cost optimization to reduce an","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","BHVN":"Biohaven Pharmaceutical Holding Co Ltd."},"translate_title":"生物制药公司Biohaven第三季度净亏损扩大至1.734亿美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BHVN":0.9},"content_text":"Biopharma firm Biohaven's Q3 net loss widens to $173.4 mlnOverviewBiohaven reports Q3 net loss of $173.4 mln, operating expenses at $169.4 mlnCompany initiates strategic cost optimization to reduce annual direct R&D spend by 60%Biohaven focuses resources on late-stage programs for epilepsy, depression, and immune diseasesOutlookBiohaven expects top-line results from Opakalim Phase 2 study in depression in 4Q 2025Company plans to initiate Phase 2 trial for Taldefgrobep alfa in obesity in 4Q 2025Biohaven aims to reduce annual direct R&D spend by approximately 60%Result DriversCOST OPTIMIZATION - Biohaven initiated strategic cost optimization to focus on late-stage clinical programsKey DetailsMetricBeat/MissActualConsensus EstimateQ3 Net Income-$173.44 mlnQ3 Basic EPS-$1.64Q3 Operating Expenses$169.38 mlnQ3 Profit From Operations-$169.38 mlnAnalyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 15 \"strong buy\" or \"buy\", 3 \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the biotechnology & medical research peer group is \"buy\"Wall Street's median 12-month price target for Biohaven Ltd is $27.00, about 69.4% above its November 7 closing price of $8.26Press Release: ID:nPn8ktwCsaFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}